Comparative Pharmacology
Head-to-head clinical analysis: MIRCETTE versus SIMPESSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIRCETTE versus SIMPESSE.
MIRCETTE vs SIMPESSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol and desogestrel; estrogen and progestin inhibit gonadotropin release, suppressing ovulation and altering cervical mucus and endometrial receptivity.
Simpesse is a combination estrogen-progestin oral contraceptive that suppresses gonadotropin release, primarily inhibiting ovulation via negative feedback on the hypothalamic-pituitary-ovarian axis. Additionally, it alters cervical mucus viscosity and endometrial receptivity.
One tablet daily for 21 days, followed by 7 placebo tablets. Each active tablet contains 0.015 mg ethinyl estradiol and 2 mg chlormadinone acetate. Route: oral.
Oral: 10 mg once daily, taken at least 1 hour before a meal.
None Documented
None Documented
Desogestrel active metabolite etonogestrel: 21-24 hours; ethinyl estradiol: 12-14 hours
Terminal elimination half-life is 24 hours (range 20-28 hours), supporting once-daily dosing.
Urine (50-60% as metabolites, <10% unchanged), feces (30-40% as metabolites)
Renal excretion of unchanged drug accounts for approximately 60-70% of elimination; hepatic metabolism produces inactive metabolites that are excreted renally (20-30%) and fecally (<10%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive